PARP1 and cancer: After Ashworth and Helleday35,36 demonstrated the synthetic lethal interactions of PARP inhibitors in BRCA1/2-deficient tumors in 2005, several inhibitors based on SL for targeted cancer therapy have been applied in clinical practice.